Revalia Bio develops curative drugs for chronic organ-centered disease.
Revalia Bio has raised $12.3M in total funding. The most recent round was Seed. The last funding was announced in October 2024.
Revalia Bio's investors include Sierra Ventures, National Kidney Foundation.
Revalia Bio is headquartered in New Haven, United States.
Revalia Bio develops curative drugs for chronic organ-centered disease.
Revalia Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Revalia Bio — Funding & Investors." VCBacked, October 29, 2024, https://www.vcbacked.co/company/revalia-bio-new-haven-2. Accessed October 21, 2026.
VCBacked. (2024). Revalia Bio — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/revalia-bio-new-haven-2
{{cite web |title=Revalia Bio — Funding & Investors |url=https://www.vcbacked.co/company/revalia-bio-new-haven-2 |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated